## Daniel J Cantillon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5183233/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker. New England Journal of Medicine, 2015, 373, 1125-1135.	27.0	410
2	Smartwatch Algorithm for AutomatedÂDetection of Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 2381-2388.	2.8	334
3	Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm, 2016, 13, 2272-2278.	0.7	285
4	Cardiac implantable electronic device infections: Presentation, management, and patient outcomes. Heart Rhythm, 2010, 7, 1043-1047.	0.7	242
5	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm, 2017, 14, e55-e96.	0.7	204
6	Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractions. Heart Rhythm, 2014, 11, 799-805.	0.7	183
7	Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm, 2010, 7, 466-471.	0.7	120
8	Catheter Ablation for Atrial Fibrillation inÂHeart Failure Patients. JACC: Clinical Electrophysiology, 2015, 1, 200-209.	3.2	86
9	Electrophysiologic characteristics and catheter ablation of ventricular tachyarrhythmias among patients with heart failure on ventricular assist device support. Heart Rhythm, 2012, 9, 859-864.	0.7	83
10	Complications and Health Care Costs Associated With Transvenous Cardiac Pacemakers in a Nationwide Assessment. JACC: Clinical Electrophysiology, 2017, 3, 1296-1305.	3.2	77
11	Atrial Fibrillation in Transthyretin Cardiac Amyloidosis. JACC: Clinical Electrophysiology, 2020, 6, 1118-1127.	3.2	72
12	Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: Analysis of the UNOS/OPTN cardiac transplant database. Heart Rhythm, 2010, 7, 1567-1571.	0.7	71
13	Implantable Cardioverter-Defibrillator UseÂin Patients With Left Ventricular AssistÂDevices. JACC: Heart Failure, 2016, 4, 772-779.	4.1	69
14	Radiofrequency Ablation of Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003669.	4.8	65
15	Recurrent Atrial Fibrillation After Initial Long-Term Ablation Success. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005785.	4.8	53
16	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. , 2017, 22, e12447.		52
17	Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm, 2015, 12, 1438-1447.	0.7	47
18	Comparative study of acute and mid-term complications with leadless and transvenous cardiac pacemakers. Heart Rhythm, 2018, 15, 1023-1030.	0.7	47

DANIEL J CANTILLON

#	Article	IF	CITATIONS
19	Evaluation and management of premature ventricular complexes. Cleveland Clinic Journal of Medicine, 2013, 80, 377-387.	1.3	35
20	Primary Results on Safety and Efficacy From the LEADLESS II–Phase 2 Worldwide Clinical Trial. JACC: Clinical Electrophysiology, 2022, 8, 115-117.	3.2	35
21	Low cardiac output associated with ventricular tachyarrhythmias in continuous-flow LVAD recipients with a concomitant ICD (LoCo VT Study). Journal of Heart and Lung Transplantation, 2014, 33, 318-320.	0.6	29
22	Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 731-737.	1.2	29
23	Long-term Outcomes and Clinical Predictors for Pacing After Cardiac Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 791-798.	0.6	27
24	Association Between Off-site Central Monitoring Using Standardized Cardiac Telemetry and Clinical Outcomes Among Non–Critically III Patients. JAMA - Journal of the American Medical Association, 2016, 316, 519.	7.4	26
25	Transvenous lead extraction at the time of cardiac implantable electronic device upgrade: Complexity, safety, and outcomes. Heart Rhythm, 2017, 14, 1807-1811.	0.7	26
26	Life-Threatening Complications ofÂAtrialÂFibrillation Ablation. JACC: Clinical Electrophysiology, 2019, 5, 284-291.	3.2	25
27	Incidence and predictors of late atrioventricular conduction recovery among patients requiring permanent pacemaker for complete heart block after cardiac surgery. Heart Rhythm, 2017, 14, 1786-1792.	0.7	21
28	Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. Heart Rhythm, 2015, 12, 517-523.	0.7	20
29	Use of virtual visits for the care of the arrhythmia patient. Heart Rhythm, 2020, 17, 1779-1783.	0.7	18
30	Transvenous Lead Extraction in Chronic Kidney Disease and Dialysis Patients With Infected Cardiac Devices. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005706.	4.8	17
31	Antitachycardia pacing for reduction of implantable cardioverter-defibrillator shocks. Heart Rhythm, 2015, 12, 1370-1375.	0.7	15
32	Long-Term Outcomes in Patients With Ambulatory New York Heart Association Class III and IV Heart Failure Undergoing Cardiac Resynchronization Therapy. American Journal of Cardiology, 2015, 115, 82-85.	1.6	15
33	Unrecognized venous injuries after cardiac implantable electronic device transvenous lead extraction. Heart Rhythm, 2018, 15, 318-325.	0.7	15
34	Implantable Cardioverter Defibrillators in Patients With Continuous Flow Left Ventricular Assist Devices: Utilization Patterns, Related Procedures, and Complications. Journal of the American Heart Association, 2019, 8, e011813.	3.7	15
35	Impact of Nonalcoholic Fatty Liver Disease on Arrhythmia Recurrence Following Atrial Fibrillation Ablation. JACC: Clinical Electrophysiology, 2020, 6, 1278-1287.	3.2	15
36	Atrial Tachyarrhythmias Among Patients With Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2019, 5, 459-466.	3.2	13

DANIEL J CANTILLON

#	Article	IF	CITATIONS
37	Catheter Ablation in Patients With Cardiogenic Shock and Refractory Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007669.	4.8	13
38	Transcatheter/leadless pacing. Heart Rhythm, 2018, 15, 624-628.	0.7	12
39	Atrial fibrillation future clinic. Novel platform to integrate smart device electrocardiogram into clinical practice. Cardiovascular Digital Health Journal, 2021, 2, 92-100.	1.3	12
40	Preclinical safety and electrical performance of novel atrial leadless pacemaker with dual-helix fixation. Heart Rhythm, 2022, 19, 776-781.	0.7	12
41	Impact of riskâ€factor modification on arrhythmia recurrence among morbidly obese patients undergoing atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1979-1986.	1.7	11
42	Clinical Characteristics and Outcomes of Non-ICU Hospitalization for COVID-19 in a Nonepicenter, Centrally Monitored Healthcare System. Journal of Hospital Medicine, 2020, 16, 7-14.	1.4	11
43	Initial arterial pH as a predictor of neurologic outcome after out-of-hospital cardiac arrest: A propensity-adjusted analysis. Resuscitation, 2019, 139, 76-83.	3.0	10
44	Cardiac venous injuries: Procedural profiles and outcomes during left ventricular lead placement for cardiac resynchronization therapy. Heart Rhythm, 2020, 17, 1298-1303.	0.7	10
45	Baseline Right Ventricular Dysfunction Predicts Worse Outcomes in Patients Undergoing Cardiac Resynchronization Therapy Implantation. Journal of Cardiac Failure, 2020, 26, 227-232.	1.7	8
46	The gap between what patients know and desire to learn about their cardiac implantable electronic devices. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 118-122.	1.2	8
47	Clinical Experience and Procedural Outcomes Associated with the DF4 Implantable Cardioverter Defibrillator System: The SJ4 Postapproval Study. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 855-862.	1.2	7
48	Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the) Tj ETQq0 0 0 rg	BT /Qverlc 1.9	ock <sub>6</sub> 10 Tf 50 3
49	Should fast pathway ablation be reconsidered in typical atrioventricular nodal reâ€entrant tachycardia?. Journal of Cardiovascular Electrophysiology, 2019, 30, 1569-1577.	1.7	6
50	Predictors of longâ€ŧerm outcomes greater than 10 years after cardiac resynchronization therapy implantation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1182-1186.	1.7	6
51	Comparative Analysis of Procedural Outcomes and Complications Between De Novo and Upgraded Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 62-72.	3.2	6
52	Leadless cardiac pacing: What primary care providers and non-EP cardiologists should know. Cleveland Clinic Journal of Medicine, 2016, 83, S24-S34.	1.3	6
53	Attenuated heart rate recovery is associated with higher arrhythmia recurrence and mortality following atrial fibrillation ablation. Europace, 2021, 23, 1063-1071.	1.7	5
54	Incidence of Cardiac Implantable Electronic Device Complications in Patients With Left Ventricular AssistÂDevices. JACC: Clinical Electrophysiology, 2021, 7, 494-501.	3.2	5

DANIEL J CANTILLON

#	Article	IF	CITATIONS
55	Are we all clear? Unintended shocks to caregivers during cardiopulmonary resuscitation. Cleveland Clinic Journal of Medicine, 2020, 87, 16-18.	1.3	5
56	Atrial Tachyarrhythmias After Cardiac Transplantation. Cardiac Electrophysiology Clinics, 2012, 4, 455-460.	1.7	4
57	Proarrhythmic effects from competitive atrial pacing and potential programming solutions. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 720-729.	1.2	4
58	Impact of High-Power Short-Duration Radiofrequency Ablation on Esophageal Temperature Dynamic. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010205.	4.8	4
59	Increasing Lesion Dimensions of Bipolar Ablation by Modulating the Surface Area of the Return Electrode. JACC: Clinical Electrophysiology, 2022, 8, 498-510.	3.2	4
60	Real-time guidewire localization using impedance-based electroanatomic mapping: experimental results and clinical validation during cryoballoon ablation of atrial fibrillation. Europace, 2013, 15, 1669-1676.	1.7	3
61	Transcutaneous carbon dioxide monitoring to avoid hypercapnia during complex catheter ablations: a feasibility study. Journal of Interventional Cardiac Electrophysiology, 2015, 43, 307-311.	1.3	3
62	Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008168.	4.8	3
63	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart, 2021, , heartjnl-2020-318333.	2.9	3
64	Efficacy of ablation at the anteroseptal line for the treatment of perimitral flutter. Journal of Arrhythmia, 2015, 31, 359-363.	1.2	2
65	Long term outcomes in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 2019, 30, 1979-1983.	1.7	2
66	Use of the Leadless Pacemaker to Provide Empiric Pacing Support for a Young Patient with Prior Ablation of a Mid-septal Accessory Pathway Resulting in Damage to the Compact AV Node. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2717-2723.	0.5	2
67	Leadless Pacemaker Technologies: Patient Selection, Approach, and Outcomes. Current Cardiovascular Risk Reports, 2018, 12, 1.	2.0	1
68	Indicationâ€specific event rates among hospitalized patients undergoing continuous cardiac monitoring. Clinical Cardiology, 2019, 42, 952-957.	1.8	1
69	Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007424.	3.9	1
70	Sudden Cardiac Death After Heart Transplantation. Cardiac Electrophysiology Clinics, 2011, 3, 609-616.	1.7	0
71	Feasibility and Usability of Patch-based Continuous Cardiac Rhythm Monitoring in Comparison with Traditional Telemetry in Noncritically III Hospitalized Patients. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3803-3808.	0.5	0
72	Abstract 23072: Unrecognized Venous Injuries After Cardiac Implantable Electronic Device Transvenous Lead Extraction. Circulation, 2017, 136, .	1.6	0